2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Peter Voorhees, MD, discusses the updated depth of response data that were reported in the GRIFFIN trial of patients with multiple myeloma.
Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the updated depth of response data that were reported in the GRIFFIN trial of patients with multiple myeloma.
The phase II GRIFFIN study is evaluating a quadruplet therapy of daratumumab (Darzalex), lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVd) or RVd alone. At the 2019 ASH Annual Meeting, updates were given on trial results.
At 24 months, the progression-free survival rate was approximately 96% in the daratumumab arm and 90% in the control arm; the 2-year overall survival rate was 96% and 93%, respectively. At the end of induction, 42% of patients treated with the quadruplet therapy were minimal residual disease (MRD) negative versus 8% treated with RVd alone. At the end of consolidation, 59% treated with the quadruplet therapy were MRD negative versus 24% of patients treated with RVd.
It will require longer follow-up to determine potential differences and more outcomes, concludes Voorhees.